Peptide Therapy | Selank, Nasal Spray - Physio Logic NYC

Description

Selank is another ACTH/MSH-like peptide of the melanocortin class most closely related to the analog tufstin. While traditionally prescribed for anxiety and depression, it has been known to be effective in many other treatments related to immune modulation, anticoagulation, PTSD, ADHD, and metabolic syndromes. For those experiencing stress-related physical tension, physical therapy in Brooklyn can provide complementary relief. Selank has pronounced anxiolytic activity and acts as a stable neuropsychotropic, antidepressant, and anti-stress drug that relieves aggression and fear reaction in different animal species. Selank also has a nootropic action, which positively influences the formation of memory and learning processes, and marked immunomodulatory activity. Clinical studies have shown that the effect of selank is similar to that of tranquilizers at low doses, but is not accompanied by the unwanted side effects of benzodiazepine tranquilizers such as amnesia, withdrawal, or dependence. Experiments have also demonstrated the effectiveness of Selank in preventing the accumulation of body fat (i.e., weight gain) with simultaneous activation of the functional state of the anticoagulation system in development of the metabolic syndrome. Furthermore, decreased blood glucose levels have been observed with chronic treatment of this peptide. The peptide Selank, like the drug Semax, induces anticoagulant and hyperglycemia effects possibly due to the presence of the same amino acid sequence, Pro-Gly-Pro, in its structure. Thus, Selank can be used as a broad-spectrum therapeutic agent for the treatment of the metabolic syndrome. Often prescribed for Anxiolytic, Immune improvement, gastric protection, as a preventative weight gain/metabolic syndrome, and with opioid and alcohol withdrawal/ dependence.

Anxiety Disorders

Selank’s primary clinical application is the management of anxiety disorders, particularly generalized anxiety disorder (GAD). Clinical data from the P-1114 study demonstrate a rapid-onset anxiolytic effect distinct from conventional treatments. Within the study cohort, 40% of patients classified as rapid responders experienced symptom reduction within 1-3 days of initiating therapy, as measured by the Hamilton Anxiety Rating Scale (HARS). The remaining 60% achieved clinically significant improvement by Day 14, indicating that Selank accommodates both fast and gradual response profiles. Unlike benzodiazepines such as diazepam or alprazolam, Selank achieves anxiolysis without the undesirable side effects of sedation, cognitive impairment, amnesia, or physiological dependence.

PTSD and Stress-Related Conditions

Selank has demonstrated potential in addressing post-traumatic stress disorder (PTSD) and chronic stress-related conditions through its effects on the fear response and hyperarousal symptoms. Animal model studies referenced in the existing clinical literature show that Selank reduces aggression and fear reactions, suggesting utility for the re-experiencing and hypervigilance components of PTSD. Additionally, Selank’s immunomodulatory activity may benefit patients with chronic stress by normalizing dysregulated cytokine profiles, providing a potential mechanism for reducing the physiological burden of long-term stress exposure.

Cognitive Performance and Nootropic Effects

Beyond its anxiolytic applications, Selank exhibits nootropic properties that support memory consolidation and learning processes. The P-1114 study data reveal that rapid responders and conventional responders differed significantly in baseline scores for asthenic and cognitive symptoms, suggesting that Selank’s cognitive benefits may be particularly relevant for patients presenting with comorbid anxiety and cognitive complaints. Unlike traditional stimulant-based nootropics, Selank enhances cognitive function through modulation of the melanocortin system without inducing jitteriness or insomnia. For patients seeking both anxiety relief and cognitive support, Selank offers a combined therapeutic approach. Learn more about Selank’s nootropic cousin, Semax for additional cognitive enhancement options.

Clinical Research

P-1114 – Rapid and Slow Response During Treatment of Generalized Anxiety Disorder with Peptide Anxiolytic Selank Results: 40% of patients were rapid responders (RR) and characterized by abrupt reduction of whole set of symptoms in first 1-3 Days. At the Day 3 Hamilton Anxiety Rating Scale (HARS) mean total score [SD] reduced from 20.3[11.9] to 7.0[2.9] (p< 0.01). 60% of patients responded gradually(conventional responders – CR). Clinically significant changes of mean HARS total score from 16.1[7.2] to 6.2[4.7] were achieved at Day 14, p< 0.01. In contrast to CR, RR demonstrated obvious EEG-reaction after single dose (900 μg) with increase of beta-rhythm, decrease of theta- and low frequencies of alpha-rhythm (all p< 0.05). Initially, RR and CR significantly differed by the score of asthenic and cognitive symptoms (p< 0.05). Peptide Therapy in Brooklyn, NY with Selank, Nasal Spray is available by prescription only. If you think Selank, Nasal Spray may be right for you, schedule a consultation with a member of our Integrative Nutrition in Brooklyn, NYC team. You can call us at 718.260.1000 or start by filling out the form below.

column_structure=””4_4″” _builder_version=”4.15″ _module_preset=””default”” background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=””{}””]